Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
10 03 2020
Historique:
pubmed: 28 1 2020
medline: 12 11 2020
entrez: 28 1 2020
Statut: ppublish

Résumé

Hypertrophic cardiomyopathy (HCM) is caused by pathogenic variants in sarcomere protein genes that evoke hypercontractility, poor relaxation, and increased energy consumption by the heart and increased patient risks for arrhythmias and heart failure. Recent studies show that pathogenic missense variants in myosin, the molecular motor of the sarcomere, are clustered in residues that participate in dynamic conformational states of sarcomere proteins. We hypothesized that these conformations are essential to adapt contractile output for energy conservation and that pathophysiology of HCM results from destabilization of these conformations. We assayed myosin ATP binding to define the proportion of myosins in the super relaxed state (SRX) conformation or the disordered relaxed state (DRX) conformation in healthy rodent and human hearts, at baseline and in response to reduced hemodynamic demands of hibernation or pathogenic HCM variants. To determine the relationships between myosin conformations, sarcomere function, and cell biology, we assessed contractility, relaxation, and cardiomyocyte morphology and metabolism, with and without an allosteric modulator of myosin ATPase activity. We then tested whether the positions of myosin variants of unknown clinical significance that were identified in patients with HCM, predicted functional consequences and associations with heart failure and arrhythmias. Myosins undergo physiological shifts between the SRX conformation that maximizes energy conservation and the DRX conformation that enables cross-bridge formation with greater ATP consumption. Systemic hemodynamic requirements, pharmacological modulators of myosin, and pathogenic myosin missense mutations influenced the proportions of these conformations. Hibernation increased the proportion of myosins in the SRX conformation, whereas pathogenic variants destabilized these and increased the proportion of myosins in the DRX conformation, which enhanced cardiomyocyte contractility, but impaired relaxation and evoked hypertrophic remodeling with increased energetic stress. Using structural locations to stratify variants of unknown clinical significance, we showed that the variants that destabilized myosin conformations were associated with higher rates of heart failure and arrhythmias in patients with HCM. Myosin conformations establish work-energy equipoise that is essential for life-long cellular homeostasis and heart function. Destabilization of myosin energy-conserving states promotes contractile abnormalities, morphological and metabolic remodeling, and adverse clinical outcomes in patients with HCM. Therapeutic restabilization corrects cellular contractile and metabolic phenotypes and may limit these adverse clinical outcomes in patients with HCM.

Sections du résumé

BACKGROUND
Hypertrophic cardiomyopathy (HCM) is caused by pathogenic variants in sarcomere protein genes that evoke hypercontractility, poor relaxation, and increased energy consumption by the heart and increased patient risks for arrhythmias and heart failure. Recent studies show that pathogenic missense variants in myosin, the molecular motor of the sarcomere, are clustered in residues that participate in dynamic conformational states of sarcomere proteins. We hypothesized that these conformations are essential to adapt contractile output for energy conservation and that pathophysiology of HCM results from destabilization of these conformations.
METHODS
We assayed myosin ATP binding to define the proportion of myosins in the super relaxed state (SRX) conformation or the disordered relaxed state (DRX) conformation in healthy rodent and human hearts, at baseline and in response to reduced hemodynamic demands of hibernation or pathogenic HCM variants. To determine the relationships between myosin conformations, sarcomere function, and cell biology, we assessed contractility, relaxation, and cardiomyocyte morphology and metabolism, with and without an allosteric modulator of myosin ATPase activity. We then tested whether the positions of myosin variants of unknown clinical significance that were identified in patients with HCM, predicted functional consequences and associations with heart failure and arrhythmias.
RESULTS
Myosins undergo physiological shifts between the SRX conformation that maximizes energy conservation and the DRX conformation that enables cross-bridge formation with greater ATP consumption. Systemic hemodynamic requirements, pharmacological modulators of myosin, and pathogenic myosin missense mutations influenced the proportions of these conformations. Hibernation increased the proportion of myosins in the SRX conformation, whereas pathogenic variants destabilized these and increased the proportion of myosins in the DRX conformation, which enhanced cardiomyocyte contractility, but impaired relaxation and evoked hypertrophic remodeling with increased energetic stress. Using structural locations to stratify variants of unknown clinical significance, we showed that the variants that destabilized myosin conformations were associated with higher rates of heart failure and arrhythmias in patients with HCM.
CONCLUSIONS
Myosin conformations establish work-energy equipoise that is essential for life-long cellular homeostasis and heart function. Destabilization of myosin energy-conserving states promotes contractile abnormalities, morphological and metabolic remodeling, and adverse clinical outcomes in patients with HCM. Therapeutic restabilization corrects cellular contractile and metabolic phenotypes and may limit these adverse clinical outcomes in patients with HCM.

Identifiants

pubmed: 31983222
doi: 10.1161/CIRCULATIONAHA.119.042339
pmc: PMC7077965
doi:

Substances chimiques

MYH7 protein, human 0
Myh6 protein, mouse 0
Adenosine Triphosphatases EC 3.6.1.-
Cardiac Myosins EC 3.6.1.-
Myosin Heavy Chains EC 3.6.4.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

828-842

Subventions

Organisme : NHLBI NIH HHS
ID : F31 HL149334
Pays : United States
Organisme : British Heart Foundation
ID : RG/12/16/29939
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/1992001/6764
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL080494
Pays : United States
Organisme : NHLBI NIH HHS
ID : P50 HL112349
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL098166
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL117006
Pays : United States
Organisme : British Heart Foundation
ID : RG/18/9/33887
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206466/Z/17/Z
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL084553
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

J Appl Physiol (1985). 2014 Jun 1;116(11):1446-54
pubmed: 24505103
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7486-E7494
pubmed: 30018063
Eur Heart J. 2018 Nov 14;39(43):3879-3892
pubmed: 29741611
Circulation. 1993 Jun;87(6):1806-15
pubmed: 8389258
J Clin Invest. 2010 Oct;120(10):3520-9
pubmed: 20811150
Elife. 2017 Jun 13;6:
pubmed: 28606303
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972
J Cardiovasc Magn Reson. 2019 Mar 14;21(1):19
pubmed: 30871562
Nat Struct Mol Biol. 2017 Jun;24(6):525-533
pubmed: 28481356
J Exp Biol. 2018 Feb 22;221(Pt 4):
pubmed: 29361606
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674652
Circulation. 2002 Jun 25;105(25):2992-7
pubmed: 12081993
Cardiovasc Res. 2017 Mar 15;113(4):411-421
pubmed: 28395011
Curr Protoc Hum Genet. 2018 Jan 24;96:21.12.1-21.12.12
pubmed: 29364522
Biophys J. 2014 Mar 18;106(6):1236-49
pubmed: 24655499
Cardiovasc Res. 2018 Aug 1;114(10):1273-1280
pubmed: 29912308
Front Physiol. 2016 Dec 16;7:562
pubmed: 28018228
Biophys Rev. 2017 Jun;9(3):225-237
pubmed: 28510118
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1355-E1364
pubmed: 28167762
Circulation. 2016 May 10;133(19):1901-5
pubmed: 27166348
N Engl J Med. 2007 Mar 15;356(11):1140-51
pubmed: 17360992
Circ Res. 2019 Apr 12;124(8):1172-1183
pubmed: 30700234
Nature. 2018 Nov;563(7731):393-396
pubmed: 30356212
J Biol Chem. 2014 Feb 21;289(8):5158-67
pubmed: 24344137
J Mol Cell Cardiol. 2016 May;94:65-71
pubmed: 27021517
Cardiovasc Res. 2005 Apr 1;66(1):12-21
pubmed: 15769444
Dev Cell. 2018 Jan 8;44(1):87-96.e5
pubmed: 29316444
Circ Res. 2005 Nov 25;97(11):1156-63
pubmed: 16224063
J Am Coll Cardiol. 2003 May 21;41(10):1776-82
pubmed: 12767664
Circulation. 1999 Nov 16;100(20):2113-8
pubmed: 10562269
Basic Res Cardiol. 1992;87 Suppl 1:129-41
pubmed: 1386730
Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11238-11243
pubmed: 30322937
Circ Res. 2013 May 24;112(11):1491-505
pubmed: 23508784
J Mol Cell Cardiol. 2010 Oct;49(4):707-8; author reply 709
pubmed: 20624395
Sci Adv. 2015 Oct 09;1(9):e1500511
pubmed: 26601291
Physiol Rev. 2011 Oct;91(4):1447-531
pubmed: 22013216
Curr Protoc Hum Genet. 2018 Jan 24;96:21.11.1-21.11.20
pubmed: 29364519
Circ Res. 2012 Jul 20;111(3):375-85
pubmed: 22821910
Science. 1996 May 3;272(5262):731-4
pubmed: 8614836
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1991-E2000
pubmed: 29444861
PLoS One. 2017 Jun 28;12(6):e0180064
pubmed: 28658286
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12607-12
pubmed: 23798412
J Physiol. 2016 Sep 15;594(18):5237-54
pubmed: 27291932
J Comp Physiol B. 2017 Jan;187(1):227-234
pubmed: 27497598
Sci Adv. 2017 Feb 10;3(2):e1601959
pubmed: 28246639
Biophys J. 2011 Apr 20;100(8):1969-76
pubmed: 21504733
Science. 2015 Aug 28;349(6251):982-6
pubmed: 26315439
Nat Commun. 2015 Aug 24;6:8054
pubmed: 26299309
Cell Metab. 2015 Feb 3;21(2):183-194
pubmed: 25651173

Auteurs

Christopher N Toepfer (CN)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
Cardiovascular Medicine, Radcliffe Department of Medicine (C.N.T., C.S.R., H.C.W.), University of Oxford, UK.
Wellcome Centre for Human Genetics (C.N.T., H.C.W.), University of Oxford, UK.

Amanda C Garfinkel (AC)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).

Gabriela Venturini (G)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor)-University of São Paulo Medical School, Brazil (G.V., A.C.P.).

Hiroko Wakimoto (H)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).

Giuliana Repetti (G)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).

Lorenzo Alamo (L)

Centro de Biología Estructural, Instituto Venezolano de Investigaciones Cientifìcas (IVIC), Caracas (L.A., R.P.).

Arun Sharma (A)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).

Radhika Agarwal (R)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).

Jourdan K Ewoldt (JK)

Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).

Paige Cloonan (P)

Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).

Justin Letendre (J)

Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).

Mingyue Lun (M)

Department of Medicine, Division of Genetics (M.L.), Brigham and Women's Hospital, Boston, MA.

Iacopo Olivotto (I)

Cardiomyopathy Unit and Genetic Unit, Careggi University Hospital, Florence, Italy (I.O.).

Steve Colan (S)

Department of Cardiology, Boston Children's Hospital, MA (S.C.).

Euan Ashley (E)

Center for Inherited Cardiovascular Disease, Stanford University, CA (E.A.).

Daniel Jacoby (D)

Department of Internal Medicine, Section of Cardiovascular Diseases, Yale School of Medicine, New Haven, CT (D.J.).

Michelle Michels (M)

Department of Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands (M.M.).

Charles S Redwood (CS)

Cardiovascular Medicine, Radcliffe Department of Medicine (C.N.T., C.S.R., H.C.W.), University of Oxford, UK.

Hugh C Watkins (HC)

Cardiovascular Medicine, Radcliffe Department of Medicine (C.N.T., C.S.R., H.C.W.), University of Oxford, UK.
Wellcome Centre for Human Genetics (C.N.T., H.C.W.), University of Oxford, UK.

Sharlene M Day (SM)

Department of Internal Medicine, University of Michigan, Ann Arbor (S.M.D.).

James F Staples (JF)

Department of Biology, University of Western Ontario, London, Canada (J.F.S.).

Raúl Padrón (R)

Centro de Biología Estructural, Instituto Venezolano de Investigaciones Cientifìcas (IVIC), Caracas (L.A., R.P.).
Division of Cell Biology and Imaging, Department of Radiology, University of Massachusetts Medical School, Worcester (R.P.).

Anant Chopra (A)

Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).

Carolyn Y Ho (CY)

Cardiovascular Division (C.Y.H., C.E.S.), Brigham and Women's Hospital, Boston, MA.

Christopher S Chen (CS)

Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).

Alexandre C Pereira (AC)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor)-University of São Paulo Medical School, Brazil (G.V., A.C.P.).

Jonathan G Seidman (JG)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).

Christine E Seidman (CE)

Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
Cardiovascular Division (C.Y.H., C.E.S.), Brigham and Women's Hospital, Boston, MA.
Howard Hughes Medical Institute, Chevy Chase, MD (C.E.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH